Bristol University spin-out Scarlet Therapeutics has raised seed funding from Science Creates Ventures and Meltwind to advance development.
Founded by blood scientists Professor Ash Toye and Professor Jan Frayne, Scarlet will use the funding to build a pipeline of novel therapies to treat rare diseases.
Therapeutic red blood cells (tRBCs) are very similar to standard red blood cells but carry additional proteins within them to provide a therapeutic benefit. Red blood cells have pervasive reach throughout the body and a long life of up to 120 days, and expressing therapeutic proteins inside the tRBCs keeps them hidden from the immune system.
